Gnosis and Green Biotechnology: Biocatalyst long-term joint research

October, 28th 2011

Gnosis Spa announced today that it has successfully concluded collaboration in biotechnology research focused on biocatalyst enzymes. Gnosis contributed its core expertise in the production of natural compounds from microorganisms to advance the development....

 

Gnosis presents a new study during the 6th Probiotics, Prebiotics & New Foods Meeting in Rome supporting Dietary Supplementation with S. boulardii and its potential role in managing Metabolic Syndrome in Obesity.

August, 2nd 2011

Gnosis S.p.A will sponsor and participate in the "6th Probiotics, Prebiotics & New Foods" symposium held in Rome September11-13 2011 at the Urbaniana University. Gnosis will present studies on dietary....

 

Gnosis makes presentation at the 2nd International Symposium "Active Pharmaceutical Ingredients from Bioprocesses: from research to industrial and regulatory issues".

July, 8th 2011

The Spanish Society of Biotechnology (SEBiot), in collaboration with Italian Biocatalysis Centre (IBC), EDQM (Council of Europe), the Complutense University of Madrid and University of Pavia....

 

Quatrefolic® is declared winner of "Most Effective Strategic Product Development" at the Nutraceutical Business & Technology (NBT) Awards.

May, 23rd 2011

Gnosis is the winner of the "Most Effective Strategic Product Development" award at the Nutraceutical Business & Technology (NBT) Awards for the unique and superior folate derivative Quatrefolic®....

 

Quatrefolic® is finalist for "Most Effective Strategic Product Development" at the Nutraceutical Business & Technology (NBT) Awards.

April, 13th 2011

Gnosis has been selected by Nutraceutical Business & Technology (NBT) Awards as one of the four finalists in the category of the "Most Effective Strategic Product Development" for the patented and registered innovative folate derivative Quatrefolic®...

 

Gnosis has received ANVISA approval to introduce the probiotic yeast Saccharomyces boulardii in Brazilian pharmaceutical market.

April, 11th 2011

Gnosis is pleased to announce that its manufacturing Operations, Gnosis Bioresearch SA, located in Sant'Antonino, Switzerland, has been successfully inspected by ANVISA, the Brazilian National Health Surveillance Agency, and has received approval for the commercialization of the probiotic yeast Saccharomyces boulardii in Brazil...

 

Gnosis extends its product portfolio and pipeline into the new APIs category of Bacteria-derived products.

March, 31st 2011

As a part of its strategic plan to become an international specialty pharmaceutical company Gnosis has achieved a new important goal of complementing its remarkably robust pipeline of products with the production of the bacteria-derived antibiotic Teicoplanin...

 

< Turn back

 

 

 

 

GNOSIS S.P.A. Sede Legale: Piazza del Carmine, 4 20121 Milano. P. IVA 02484720129 C. F. 10197170151 Cap. Soc. 3.000.000,00 € i.v. Registro delle imprese di Milano N° 10197170151